focus -WSS

focus

author：knowledge 2025-09-30 20:06:45 - browse：282

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Why Medicare shouldn’t cover every FDA

WSS

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Investment in vaccine development is lagging, report finds

New clues to why women have higher risk of autoimmune disorders

An inside look at PIPEs, biotech's buzzy new financing tool

Why getting cancer drugs just got harder for rural patients

Merck, Johnson & Johnson CEOs will testify on high drug prices

entertainment

focus

focus

In Memoriam: Notable people who died in 2023

How to address the problem of discarded donor organs

In Memoriam: Notable people who died in 2023

Wegovy leads to weight loss. Can it treat depression, too?

BioMarin wins approval for gene therapy to treat hemophilia A

Health Care Service Corp to buy Cigna Medicare Advantage plans

After affirmative action ruling, medical educators look to 'holistic review'

Biotech companies concerned about China biosecurity crackdown

Apple is now the first public company to be valued at $3 trillion

FDA does about

knowledge

In search for therapies for solid tumors, companies turn to claudin

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Pancreatic cancer early detection could be helped by AI

Bernie Sanders is gearing up to subpoena pharma CEOs

How generative AI ratchets up security threats for health systems

RaDonda Vaught to speak at CommonSpirit event on patient safety

focus

leisure time

leisure time

knowledge